DOD Duchenne Muscular Dystrophy, Idea Development Award | HT942524DMDRPIDA

Opportunity Information: Apply for HT942524DMDRPIDA

The FY24 Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) is a grant opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) that is meant to push the field forward by funding early-stage, conceptually bold research in Duchenne muscular dystrophy (DMD). The central aim is to support new ideas that are not yet fully developed but have a clear chance to generate impactful data and open up fresh directions for DMD investigation. The program is explicitly geared toward high-risk, high-reward projects that could realistically lead to major advances or critical discoveries that help accelerate progress toward better outcomes for people living with DMD. Applications are expected to be built around a well-formulated and testable hypothesis, backed by strong scientific rationale.

A major emphasis of the IDA is innovation and impact, and applicants are expected to spell both out clearly rather than assuming reviewers will infer them. Innovation, in the context of this award, means more than incremental improvement: it can involve introducing a new paradigm, challenging prevailing assumptions, applying a new lens to an old problem, or proposing a uniquely creative approach. Impact is framed as the project’s potential to meaningfully accelerate the DMD field, including the possibility of enabling new strategies, reshaping understanding of disease biology, improving diagnostics, or otherwise moving the needle toward improved patient outcomes. Importantly, even if a project will not produce immediate clinical benefit, the applicant still needs to articulate how it could ultimately matter for DMD research and for individuals with DMD. Projects that are scientifically strong but do not convincingly demonstrate both innovation and high potential impact are described as not meeting the intent of the award.

The opportunity is also structured to encourage participation from “New Investigators,” including independent investigators early in their careers (generally within 10 years of their first faculty appointment or equivalent) as well as established investigators who are new to DMD research. Within the New Investigator track, the funding opportunity distinguishes between two categories: New Investigator - Early Stage, which allows applicants who are early in faculty appointments to compete in a separate pool from established investigators, and New Investigator - Transitioning, which is designed for investigators (at or above the Assistant Professor level) coming from fields outside muscular dystrophy who want to transition their expertise into DMD. New Investigator applications and Established Investigator applications are peer reviewed and programmatically reviewed in separate tracks, which is intended to create a fairer competitive environment. New Investigators are strongly encouraged to build collaborations with researchers who have DMD experience and/or other key expertise needed for the project, and the applicant must explain specifically how those collaborations fill gaps and strengthen the team’s ability to answer the research question. Eligibility for the New Investigator categories is tied to criteria laid out in the official eligibility section of the announcement.

Unlike some early-concept awards that accept purely speculative proposals, this IDA requires preliminary data relevant to DMD to demonstrate feasibility. That supporting evidence can include unpublished findings generated by the principal investigator, the research team, or named collaborators. In practice, this means applicants should be prepared to show enough proof-of-concept to justify the approach while still keeping the project squarely in the innovative, early-development space the program is trying to cultivate.

Clinical trials are not permitted under this funding opportunity. The announcement applies the federal definition of a clinical trial (45 CFR 46.102): studies in which human subjects are prospectively assigned to an intervention (including placebo or control) to evaluate effects on biomedical or behavioral health-related outcomes. If a study is designed to measure safety, effectiveness, or efficacy outcomes of an intervention, it falls into clinical trial territory and would be disallowed here. At the same time, the program makes clear that certain kinds of clinical research are allowed as long as they remain observational and do not test an intervention’s safety or efficacy. Examples of allowable clinical research include studies using human data or specimens to understand disease mechanisms, develop or validate diagnostics (such as biomarkers or imaging approaches), examine health disparities, develop new technologies, conduct epidemiologic or behavioral studies that are not intervention-evaluation trials, and conduct outcomes or health services research that does not meet the clinical trial definition. The announcement also notes that certain in vitro work using de-identified human data or specimens that cannot be linked to living individuals may be excluded from the definition of clinical research if it qualifies for exemption under the Common Rule.

From an administrative standpoint, the opportunity is a discretionary grant in the Science and Technology and other Research and Development category (CFDA 12.420), with unrestricted eligibility listed in the source summary. The funding opportunity number is HT942524DMDRPIDA, with an original closing date of August 22, 2024. The source summary lists an expected number of eight awards, and the posting is attributed to the Department of the Army (USAMRAA).

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Duchenne Muscular Dystrophy, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-05-07.
• Applicants must submit their applications by 2024-08-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 8 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524DMDRPIDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: